Prelude Therapeutics Inc - Asset Resilience Ratio
Prelude Therapeutics Inc (PRLD) has an Asset Resilience Ratio of 7.84% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PRLD working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Prelude Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Prelude Therapeutics Inc.
Liquid Assets Composition Over Time
This chart breaks down Prelude Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PRLD total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.42 Million | 7.84% |
| Total Liquid Assets | $7.42 Million | 7.84% |
Asset Resilience Insights
- Limited Liquidity: Prelude Therapeutics Inc maintains only 7.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Prelude Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Prelude Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Prelude Therapeutics Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Prelude Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.02% | $121.14 Million | $175.51 Million | -5.76pp |
| 2023-12-31 | 74.78% | $207.64 Million | $277.67 Million | -2.82pp |
| 2022-12-31 | 77.61% | $171.12 Million | $220.50 Million | -7.42pp |
| 2021-12-31 | 85.02% | $259.40 Million | $305.10 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $223.59 Million | -- |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more